ArticleOncology reports2022

[Corrigendum] TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma.

Song Ye et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.